Mergers & Acquisitions Mergers & Acquisitions

AstraZeneca files $39 billion acquisition of Alexion Pharmaceuticals for EU review

By Natalie McNelis
  • 01 Jun 2021 05:35
  • 01 Jun 2021 05:35
Drugmaker AstraZeneca has requested EU approval to acquire US rival Alexion Pharmaceuticals, according to an update today on the European Commission's register of deals.

The commission has set a July 5 deadline to decide on the deal.

AstraZeneca said it plans to buy Alexion for $39 billion, to establish a “greater scientific presence”

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News